230 related articles for article (PubMed ID: 30873648)
1. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review.
Khan S; Rupniewska E; Neighbors M; Singer D; Chiarappa J; Obando C
J Clin Pharm Ther; 2019 Aug; 44(4):495-507. PubMed ID: 30873648
[TBL] [Abstract][Full Text] [Related]
2. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
3. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
Cai Q; Ding Z; Fu AZ; Patel AA
BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
[TBL] [Abstract][Full Text] [Related]
4. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.
Chen C; Hartzema AG; Xiao H; Wei YJ; Chaudhry N; Ewelukwa O; Glover SC; Zimmermann EM
Inflamm Bowel Dis; 2019 Jul; 25(8):1417-1427. PubMed ID: 30839057
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
Little DHW; Tabatabavakili S; Shaffer SR; Nguyen GC; Weizman AV; Targownik LE
Am J Gastroenterol; 2020 Nov; 115(11):1768-1774. PubMed ID: 33156094
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases.
Moran K; Null K; Huang Z; Lissoos T; Kane S
Adv Ther; 2019 Sep; 36(9):2260-2272. PubMed ID: 31385283
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
[TBL] [Abstract][Full Text] [Related]
9. Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications.
Lee S; Seow CH; Adhikari K; Metcalfe A
Aliment Pharmacol Ther; 2020 Mar; 51(5):544-552. PubMed ID: 31797416
[TBL] [Abstract][Full Text] [Related]
10. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
[TBL] [Abstract][Full Text] [Related]
11. Adherence to subcutaneous biologic treatment for inflammatory bowel disease.
Ramos L; Ramos-Rodríguez J; Barreda R; Gutiérrez-Nicolás F; Carrillo-Palau M; Alonso-Abreu I; Nazco-Casariego J; Quintero E
Gastroenterol Hepatol; 2022 May; 45(5):335-341. PubMed ID: 34051312
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence.
Gemayel NC; Rizzello E; Atanasov P; Wirth D; Borsi A
Curr Med Res Opin; 2019 Nov; 35(11):1911-1923. PubMed ID: 31192706
[No Abstract] [Full Text] [Related]
13. Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.
Kariburyo MF; Xie L; Teeple A; Tan H; Ingham M
Adv Ther; 2017 Jun; 34(6):1398-1410. PubMed ID: 28484953
[TBL] [Abstract][Full Text] [Related]
14. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review.
Lopez A; Billioud V; Peyrin-Biroulet C; Peyrin-Biroulet L
Inflamm Bowel Dis; 2013 Jun; 19(7):1528-33. PubMed ID: 23518810
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases.
Huoponen S; Blom M
PLoS One; 2015; 10(12):e0145087. PubMed ID: 26675292
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity.
Murage MJ; Anderson A; Casso D; Oliveria SA; Ojeh CK; Muram TM; Merola JF; Zbrozek A; Araujo AB
J Dermatolog Treat; 2019 Mar; 30(2):141-149. PubMed ID: 29799292
[TBL] [Abstract][Full Text] [Related]
18. Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review.
Nieto JC; Arajol C; Carmona L; Marras C; Cea-Calvo L
Immunotherapy; 2021 Apr; 13(5):433-458. PubMed ID: 33557600
[No Abstract] [Full Text] [Related]
19. High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease.
San EH; Egberts A; van Dijck-van Boetzelaer CWT; West RL; Vasbinder EC
Eur J Clin Pharmacol; 2024 Jul; 80(7):1089-1096. PubMed ID: 38553558
[TBL] [Abstract][Full Text] [Related]
20. The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases.
Kluthe C; Tsui J; Spady D; Carroll M; Wine E; Huynh HQ
Can J Gastroenterol Hepatol; 2018; 2018():4687041. PubMed ID: 29682493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
